1. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
   Yammy Yung et al, 2021, IJMS CrossRef
2. Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia
   Dongfeng Zhang et al, 2021, J. Med. Chem. CrossRef
3. Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
   Raquel Alves et al, 2021, Cancers CrossRef
4. Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
   Sara Malik et al, 2021, Expert Review of Hematology CrossRef
5. Copper-Containing Nanoparticles and Organic Complexes: Metal Reduction Triggers Rapid Cell Death via Oxidative Burst
   Sergey A. Tsymbal et al, 2021, IJMS CrossRef
6. null
   Rajesh Kumar et al, 2022 CrossRef
7. Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New Agents
   Massimo Breccia et al, 2022, CCDT CrossRef
8. Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation
   Sultan Tousif et al, 2023, Circulation Research CrossRef
9. Rhodanine Derivatives as Anticancer Agents: QSAR and Molecular Docking Studies
   Maja Molnar et al, 2023, ACAMC CrossRef
10. A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
    Rasha Kaddoura et al, 2023, Front. Med. CrossRef
11. Molecular modeling in synthesis: from statistical methods to quantum chemistry and practical applications
    I. V. Svitanko et al, 2024, Russ Chem Bull CrossRef